XTX Markets’s Heron Therapeutics HRTX Stock Holding History

XTX Markets’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-11,575	Closed	-$172K	–	216
2020 Q3	$172K	Buy	+11,575	New	+$181K	0.83%	67

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

XTX Markets's HRTX Position: Q4 2020 in Review

XTX Markets sold out of Heron Therapeutics (HRTX) in Q4 2020, closing a stake of 11,575 shares — an estimated $172K sold.

XTX Markets first reported a position in HRTX in Q3 2020 and held it in 1 quarter. The position peaked at $172K in Q3 2020. 189 funds tracked by Wall St. Rank hold HRTX as of Q4 2020.

XTX Markets reported no remaining Heron Therapeutics position as of Q4 2020 after selling out during the quarter.
XTX Markets sold 11,575 Heron Therapeutics shares in Q4 2020, an estimated $172K.
XTX Markets first reported a position in Heron Therapeutics in Q3 2020 and held it in 1 quarter.
XTX Markets's Heron Therapeutics position peaked at $172K in Q3 2020.
189 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2020.

Based on XTX Markets's 13F filing for Q4 2020, filed 25 Jan 2021.